Apple Tree Partners related stories
All articles and analysis
Apple Tree Partners announces promotionsNew York-based Apple Tree Partners, a life sciences venture firm, has made a number of promotions. Dr. Sam Hall and Aaron Kantoff are now partners; Dr. Christine Borowski has become a principal; and Dr. Jernej Godec and Dr. Chris Cain have become senior associates.
- Akero Therapeutics locks in $70 mln Series B
Cambridge, Massachusetts-based Akero Therapeutics Inc, a biotechnology company focused on treating non-alcoholic steatohepatitis and other serious metabolic diseases, has raised $70 million in Series B funding. Janus Henderson Investors led the round with participation from Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, LifeSci Venture Partners, Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.
- Stoke Therapeutics inks $90 mln Series B
Bedford, Massachusetts-based Stoke Therapeutics, a biotech firm, has raised $90 million in Series B financing. RTW Investments led the round with participation from other investors that included Apple Tree Partners, RA Capital Management, Cormorant Asset Management, Perceptive Advisors, funds managed by Janus Henderson Investors, Redmile Group, Sphera Funds Management and Alexandria Venture Investments.
- Akero Therapeutics scores $65 mln Series A
Cambridge, Massachusetts-based Akero Therapeutics Inc, a biotechnology company focused on treating non-alcoholic steatohepatitis and other serious metabolic diseases, has raised $65 million in Series A financing. Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures led the round.
- Braeburn Pharmaceuticals racks up $110 mln
Braeburn Pharmaceuticals, which provides treatment solutions for opioid addiction, has secured $110 million in financing. Wellington Capital Management led the round with participation from other investors that included Avista Capital Partners, RA Capital Management, New Leaf Venture Partners, Deerfield Management, Rock Springs Capital and Apple Tree Partners.
- Stoke Therapeutics hauls in $40 mln Series A
Bedford, Massachusetts-based Stoke Therapeutics Inc, which works to increase gene expression to treat diseases caused by genetic insufficiency, has raised $40 million in Series A financing. Apple Tree Partners led the round.
- Elstar Therapeutics locks in $39 mln Series A
Cambridge, Massachusetts-based Elstar Therapeutics, a provider of precision cancer immunotherapy, has raised $39 million in Series A financing. The investor was Apple Tree Partners.
- Syntimmune gathers $50 mln Series B in Apple Tree-led round
Waltham, Massachusetts and New York City-based Syntimmune Inc, a biotech company, has secured $50 million in Series B financing. Apple Tree Partners led the round.
- Opioid addiction implant maker Braeburn Pharma pulls IPO: Reuters
Braeburn Pharmaceuticals Inc, the maker of the first long-acting implant to treat opioid addiction in the United States, said on Thursday that it had decided not to proceed with its initial public offering, citing current market environment.